Lindbrook Capital’s Mereo BioPharma MREO Stock Holding History

Lindbrook Capital’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,665	Closed	-$5.83K	–	2888
2024 Q4	$5.83K	Hold	1,665	–	–	﹤0.01%	1915
2024 Q3	$6.84K	Hold	1,665	–	–	﹤0.01%	1870
2024 Q2	$5.99K	Sell	1,665 -635	-28%	-$2.06K	﹤0.01%	1905
2024 Q1	$7.59K	Buy	+2,300	New	+$7.79K	﹤0.01%	1710
2021 Q3	–	Sell	-5,000	Closed	-$16K	–	1948
2021 Q2	$16K	Buy	+5,000	New	+$16.8K	﹤0.01%	864
2021 Q1	–	Sell	-5,000	Closed	-$18K	–	1916
2020 Q4	$18K	Buy	+5,000	New	+$12.5K	﹤0.01%	722

Other funds holding MREO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Lindbrook Capital's MREO Position: Q1 2025 in Review

Lindbrook Capital sold out of Mereo BioPharma (MREO) in Q1 2025, closing a stake of 1,665 shares — an estimated $5.83K sold.

Lindbrook Capital first reported a position in MREO in Q4 2020 and held it in 6 quarters. The position peaked at $18K in Q4 2020. 90 funds tracked by Wall St. Rank hold MREO as of Q1 2025.

Lindbrook Capital reported no remaining Mereo BioPharma position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 1,665 Mereo BioPharma shares in Q1 2025, an estimated $5.83K.
Lindbrook Capital first reported a position in Mereo BioPharma in Q4 2020 and held it in 6 quarters.
Lindbrook Capital's Mereo BioPharma position peaked at $18K in Q4 2020.
90 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.